Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.080
-0.100 (-8.47%)
At close: Oct 29, 2024, 4:00 PM
1.090
+0.010 (0.93%)
After-hours: Oct 29, 2024, 7:55 PM EDT

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
--0.050.45-
Revenue Growth (YoY)
---89.98%--
Cost of Revenue
--0.010.09-
Gross Profit
--0.030.36-
Selling, General & Admin
17.4515.9815.96.163.59
Research & Development
12.1213.017.263.83.18
Operating Expenses
29.5728.9923.169.966.77
Operating Income
-29.57-28.99-23.13-9.61-6.77
Interest Expense
-1.07-1.07-0.16-0.61-0.16
Other Non Operating Income (Expenses)
7.881.33-2.130.24-1.05
EBT Excluding Unusual Items
-22.75-28.73-25.42-9.98-7.99
Other Unusual Items
-0.47-0.47--0.060.06
Pretax Income
-23.23-29.2-25.42-10.92-7.93
Income Tax Expense
0.020.020.010.010
Net Income
-23.25-29.22-25.43-10.93-7.94
Net Income to Common
-24.92-29.22-25.43-10.93-7.94
Shares Outstanding (Basic)
32122
Shares Outstanding (Diluted)
32122
Shares Change (YoY)
1173.82%98.55%-56.93%15.26%-
EPS (Basic)
-7.17-17.30-29.90-5.54-4.63
EPS (Diluted)
-7.17-17.30-29.90-5.54-4.63
Free Cash Flow
-28.18-27.57-13.64-7.98-5.18
Free Cash Flow Per Share
-8.11-16.32-16.04-4.04-3.02
Gross Margin
--68.89%79.06%-
Operating Margin
---51395.56%-2139.42%-
Profit Margin
---56504.44%-2434.97%-
Free Cash Flow Margin
---30315.56%-1777.28%-
EBITDA
-29.18-28.6-22.87-9.45-6.67
D&A For EBITDA
0.390.390.260.160.11
EBIT
-29.57-28.99-23.13-9.61-6.77
Revenue as Reported
--0.05--
Source: S&P Capital IQ. Standard template. Financial Sources.